Short Communication - (2025) Volume 9, Issue 4
Received: 01-Jul-2025, Manuscript No. hps-26-184466;
Editor assigned: 03-Jul-2025, Pre QC No. P-184466;
Reviewed: 17-Jul-2025, QC No. Q-184466;
Revised: 22-Jul-2025, Manuscript No. R-184466;
Published:
29-Jul-2025
, DOI: 10.37421/2573-4563.2025.9.361
Citation: Mitchell, Hannah L.. ”Hepatic Stellate Cells: Inflammation,Fibrosis, and Therapeutic Targeting.” J Hepatol Pancreat Sci 09 (2025):361.
Copyright: © 2025 Mitchell L. Hannah This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Hepatic stellate cells (HSCs) are recognized as pivotal cellular players in the complex pathogenesis of liver inflammation and fibrosis. Upon sensing diverse injury signals within the liver microenvironment, these quiescent cells undergo a remarkable transformation into activated myofibroblast-like cells. This activation is the primary driver of excessive extracellular matrix (ECM) deposition and subsequent scar formation, hallmarks of fibrotic liver disease. The intricate process of HSC activation is deeply intertwined with the release of inflammatory cytokines by resident and infiltrating immune cells, which in turn further stimulate HSC activity and matrix production, creating a self-perpetuating cycle of damage [1].
The activation of hepatic stellate cells represents a critical cellular event in the evolutionary trajectory of liver fibrosis. This cellular transformation is orchestrated by a multifaceted interplay involving a range of growth factors, signaling cytokines, and chemokines. These soluble mediators are frequently released by immune cells that infiltrate the liver in response to acute or chronic injury. Consequently, precisely targeting these specific signaling pathways that govern HSC activation emerges as a promising and novel therapeutic avenue for the prevention or reversal of fibrotic scarring in the liver [2].
Inflammatory mediators, with a particular emphasis on key cytokines such as transforming growth factor-beta (TGF-β) and tumor necrosis factor-alpha (TNF-α), exert a profound influence on modulating hepatic stellate cell behavior during periods of liver injury. These potent signaling molecules not only promote the activation and proliferative capacity of HSCs but also significantly enhance their ability to synthesize and secrete extracellular matrix proteins, thereby directly contributing to the fibrotic process. A comprehensive understanding of these cytokine-driven molecular cascades is therefore absolutely essential for the rational design and implementation of effective therapeutic interventions aimed at mitigating liver fibrosis [3].
Contemporary research has begun to illuminate the significant heterogeneity that exists within hepatic stellate cell populations and to delineate their diverse and often context-dependent roles in various liver pathologies. Beyond their well-established differentiation into myofibroblasts, HSCs have been observed to adopt distinct pro-inflammatory phenotypes. In this capacity, they can actively contribute to the recruitment and subsequent activation of immune cells within the liver, underscoring the complex cellular plasticity that underpins their central involvement in both inflammatory responses and the pathological progression of fibrotic liver disease [4].
The dynamic interplay between inflammatory processes and fibrotic development within the liver is heavily influenced and shaped by the functional state of hepatic stellate cells. Activated HSCs possess the dual capability of not only producing excessive amounts of extracellular matrix but also secreting various inflammatory mediators. These secreted factors can recruit and activate resident and circulating immune cells, thereby establishing a self-reinforcing cycle of liver damage and chronic inflammation. Consequently, therapeutically targeting this critical crosstalk between inflammation and HSC function represents a particularly promising strategy for managing liver fibrosis [5].
Epigenetic modifications, encompassing a range of heritable changes in gene expression that do not involve alterations to the underlying DNA sequence, play a crucially important role in regulating both the initial activation and the sustained pro-fibrotic phenotype of hepatic stellate cells. Investigating these intricate epigenetic changes, such as DNA methylation patterns and various histone modifications, holds the potential to unveil novel therapeutic targets. By modulating HSC behavior through epigenetic means, it may become possible to effectively reverse or prevent the progression of liver fibrosis [6].
The functional significance of extracellular vesicles (EVs), particularly those released by activated hepatic stellate cells, is increasingly recognized as an important factor contributing to the progression of liver inflammation and fibrosis. These nanoscale vesicles can encapsulate and transport a diverse array of bioactive molecules, including proteins, lipids, and nucleic acids. Upon release, they can influence the behavior of neighboring cells, including immune cells and hepatocytes, thereby modulating the fibrotic process and shaping the inflammatory milieu within the liver [7].
Targeting hepatic stellate cells directly represents a highly promising and rational therapeutic strategy for the management of liver fibrosis. Interventions aimed at inhibiting HSC activation or, alternatively, promoting their return to a quiescent state, potentially through the modulation of specific inflammatory signaling pathways or the targeting of unique cell surface receptors, could effectively halt or even reverse fibrotic progression across a spectrum of liver diseases. This approach offers a potentially disease-modifying therapeutic avenue [8].
The intricate relationship between the gut microbiota and the liver, often referred to as the gut-liver axis, profoundly influences hepatic stellate cell activation and the subsequent development of liver fibrosis. Disruptions in the gut microbial community, known as dysbiosis, and the resultant inflammatory signals emanating from the gut can significantly exacerbate HSC activation. This exacerbation contributes directly to the overall progression of chronic liver disease, highlighting the critical importance of considering these systemic factors in the context of fibrotic liver pathology [9].
Inflammasomes, which are intracellular multi-protein complexes known for their critical role in initiating inflammatory responses by activating inflammatory caspases, are increasingly recognized for their significant contribution to both liver inflammation and fibrosis. These molecular platforms can directly influence the activation status and overall function of hepatic stellate cells, thereby contributing to the inflammatory cascade that ultimately drives the process of fibrogenesis within the liver [10].
Hepatic stellate cells (HSCs) are central to liver pathology, acting as key effectors in inflammatory and fibrotic processes. When exposed to injury signals, HSCs transition from a quiescent state to an activated myofibroblast-like phenotype, which is characterized by robust extracellular matrix deposition and scar tissue formation. This activation is heavily influenced by inflammatory cytokines secreted by immune cells, creating a feedback loop that amplifies HSC activation and matrix production. Consequently, understanding the complex molecular interactions involving HSCs is fundamental for devising targeted therapeutic strategies for liver diseases [1].
The activation of hepatic stellate cells is a pivotal event in the development and progression of liver fibrosis. This cellular transformation is driven by a complex network of signaling molecules, including growth factors, cytokines, and chemokines, many of which are released by immune cells responding to liver injury. Therefore, inhibiting these specific signaling pathways presents a significant opportunity for developing novel therapeutic approaches aimed at preventing or even reversing fibrotic liver damage [2].
Key inflammatory mediators, notably cytokines like TGF-β and TNF-α, play a critical role in governing the behavior of hepatic stellate cells during liver injury. These signaling molecules not only promote HSC activation and proliferation but also enhance their capacity to produce extracellular matrix proteins, which directly contributes to the development of liver fibrosis. Elucidating these cytokine-dependent signaling pathways is crucial for the development of effective therapeutic interventions targeting liver fibrosis [3].
Recent scientific advancements have underscored the considerable heterogeneity among hepatic stellate cells and have revealed their diverse functional roles in liver disease. Apart from differentiating into myofibroblasts, HSCs can also acquire pro-inflammatory properties, contributing to the recruitment and activation of immune cells within the liver. This inherent cellular plasticity is central to their involvement in both inflammatory responses and the exacerbation of fibrotic progression [4].
The intricate interplay between liver inflammation and fibrosis is significantly modulated by the functional status of hepatic stellate cells. Activated HSCs not only contribute to ECM production but also secrete inflammatory factors that attract and activate immune cells, establishing a vicious cycle of liver damage. Targeting this critical crosstalk between inflammatory signals and HSC function is considered a highly promising therapeutic strategy for liver fibrosis [5].
Epigenetic mechanisms, such as DNA methylation and histone modifications, are critical regulators of hepatic stellate cell activation and their sustained pro-fibrotic phenotype. A deeper understanding of these epigenetic changes can reveal novel therapeutic targets for reversing or preventing liver fibrosis by influencing HSC behavior and function [6].
Extracellular vesicles (EVs) released by hepatic stellate cells are emerging as important mediators in liver inflammation and fibrosis. These vesicles carry molecules that can affect the behavior of surrounding cells, including immune cells and hepatocytes, thereby influencing the fibrotic process and the inflammatory environment of the liver [7].
Targeting hepatic stellate cells offers a potent therapeutic strategy for managing liver fibrosis. Inhibiting HSC activation or promoting their quiescent state, possibly by modulating inflammatory signaling or targeting specific cell surface receptors, could effectively halt or reverse fibrotic progression in various liver conditions [8].
The gut-liver axis plays a significant role in hepatic stellate cell activation and the pathogenesis of liver fibrosis. Gut dysbiosis and subsequent inflammatory signals from the gut can amplify HSC activation, contributing to the advancement of liver disease. This underscores the importance of considering the influence of systemic factors on fibrotic liver disease [9].
Inflammasomes, intracellular protein complexes involved in activating inflammatory caspases, are increasingly recognized for their contribution to liver inflammation and fibrosis. They can directly impact hepatic stellate cell activation and function, thereby exacerbating the inflammatory cascade that drives fibrogenesis [10].
Hepatic stellate cells (HSCs) are central to liver inflammation and fibrosis. Upon activation by injury signals, they transform into myofibroblast-like cells, leading to extracellular matrix deposition and scar formation. This process is fueled by inflammatory cytokines released by immune cells, further activating HSCs and matrix production. Targeting these signaling pathways and HSC activation is a promising therapeutic strategy. Epigenetic modifications and extracellular vesicles released by HSCs also play crucial roles. The gut-liver axis, through gut dysbiosis, can exacerbate HSC activation and fibrosis. Inflammasomes contribute to the inflammatory cascade driving fibrogenesis. Understanding these complex interactions is key to developing effective treatments for liver diseases.
None
None
Hepatology and Pancreatic Science received 34 citations as per Google Scholar report
